{"id":1797,"date":"2014-10-20T19:30:00","date_gmt":"2014-10-20T17:30:00","guid":{"rendered":"http:\/\/www.aidsmap.com\/page\/2915298\/"},"modified":"2014-10-20T19:30:00","modified_gmt":"2014-10-20T17:30:00","slug":"sofosbuvirledipasvir-safe-and-effective-for-genotype-1-hcv","status":"publish","type":"post","link":"http:\/\/www.asamilano30.org\/?p=1797","title":{"rendered":"Sofosbuvir\/ledipasvir safe and effective for genotype 1 HCV"},"content":{"rendered":"

A single-tablet
\nregimen containing the hepatitis C virus (HCV) nucleotide polymerase
\ninhibitor sofosbuvir and
\nthe NS5A inhibitor ledipasvir - the combination in Gilead Science’s
\nrecently approved Harvoni pill - was well-tolerated and cured 97% of
\npatients with HCV genotype 1 in the Phase 3 ION trials, researchers
\nreported at the IDWeek 2014 meeting earlier this month in
\nPhiladelphia.
\nThe
\nadvent of direct-acting antiviral agents has revolutionized treatment for
\nchronic hepatitis C, especially with the long-awaited<\/p>\n","protected":false},"excerpt":{"rendered":"

A single-tablet
\nregimen containing the hepatitis C virus (HCV) nucleotide polymerase
\ninhibitor sofosbuvir and
\nthe NS5A inhibitor ledipasvir – the combination in Gilead Science’s
\nrecently approved Harvoni pill – was well-tolerated and cured 97% of
\npatients with HCV genotype 1 in the Phase 3 ION trials, researchers
\nreported at the IDWeek 2014 meeting earlier this month in
\nPhiladelphia.
\nThe
\nadvent of direct-acting antiviral agents has revolutionized treatment for
\nchronic hepatitis C, especially with the long-awaited<\/p>\n","protected":false},"author":93,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0},"categories":[1],"tags":[5,6,9],"_links":{"self":[{"href":"http:\/\/www.asamilano30.org\/index.php?rest_route=\/wp\/v2\/posts\/1797"}],"collection":[{"href":"http:\/\/www.asamilano30.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.asamilano30.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.asamilano30.org\/index.php?rest_route=\/wp\/v2\/users\/93"}],"replies":[{"embeddable":true,"href":"http:\/\/www.asamilano30.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1797"}],"version-history":[{"count":4,"href":"http:\/\/www.asamilano30.org\/index.php?rest_route=\/wp\/v2\/posts\/1797\/revisions"}],"predecessor-version":[{"id":1811,"href":"http:\/\/www.asamilano30.org\/index.php?rest_route=\/wp\/v2\/posts\/1797\/revisions\/1811"}],"wp:attachment":[{"href":"http:\/\/www.asamilano30.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.asamilano30.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1797"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.asamilano30.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}